April 4, 2022 5:02pm

A break-out or a fake-out as momentum surges; the algorithms getting hungry

Pre-open indications: 5 Hits, 2 MISS and 1 Pimp/Pump and Promote – the usual suspect, Biostage (BSTG)with 8,809 shares traded after Friday’s $0.00 with 10 shares traded following Thursday’s 124 shares trading -$0.10. Out of nowhere comes the shares, – who is kidding whom a gift from China?

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?

 

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +103.87 points (+0.30%); the S&P closed UP +36.76 points (+0.81%) while the Nasdaq closed UP +271.05 points (+1.90%)

 

Henry’omics:

Indexes traded higher on Monday …

“With bonds selling off and commodities at the mercy of geopolitics, there just aren’t many attractive investment opportunities outside of the stock market. That sets the stage for some choppy trading, until it becomes clearer whether a recession is really on the cards.” <MarketWatch>

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Monday opened positive at 24 up/10 downs, 1 flat, stayed positive at the mid-day at31/3, ending with a positive close of 31/4
  • Friday opened positive at 28 up/5 downs, 2 flats, stayed positive at the mid-day at 25/8 and 2 flats, ending with a positive close of 27/6 and 2 flats;

 

Pre-open Indications: 5 Hits < AVROBIO (AVRO +$0.08), Beam Therapeutics (BEAM +$2.41), CRISPR Therapeutics (CRSP +$3.36); SELL into Strength: Fate Therapeutics (FATE +$1.07), Cellectis SA (CLLS +$0.08)> 2 Miss < Ionis Pharmaceuticals (IONS -$0.17), Global Blood Therapeutics (GBT +$1.39)> 1 Pimp/Pump/Promote: Biostage (BSTG) closed up +$0.49 with 8,809 shares traded after Friday’s $0.00 with 10 shares traded, Thursday’s -$0.10 with 124 shares traded, Wednesday’s +$0.50 with 3,926 shares traded and las Tuesday’s -$0.50 with 3,300 shares traded),     

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  … added with 35 to date <some dropped and others added>

 

Key Metrics:

  • Monday - Sector volume was LOW with 11 of the 31-upside having higher than the 3-month average volume with LOW volume of 2 of 4-downside having higher than the 3-month average volume;
  • Friday - Sector volume was LOW with 8 of the 27-upside having higher than the 3-month average volume with LOW volume of 1 of 6-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB was up +1.28% and the XBI was up +3.03%
  • Friday, the IBB was up +2.12% and the XBI was up +3.76%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was down -1.06 points or -5.40% at 18.57
  • Friday was down -0.93 points or -4.52% at 19.63

 

Jumping with share pricing momentum (10 of 31):

  • CRISPR Therapeutics (CRSP +$3.36 after Friday’s +$3.38),
  • Beam Therapeutics (BEAM +$2.41 after Friday’s +$2.65),
  • Global Blood Therapeutics (GBT +$1.39),
  • Editas Medicine (EDIT +$1.13),
  • Fate Therapeutics (FATE +$1.07 after Friday’s +$2.55),
  • uniQure NV (QURE +$1.00 after Friday’s +$1.38),
  • Sage Therapeutics (SAGE +$0.99 after Friday’s +$3.90),
  • Ultragenyx (RARE +$0.78 after Friday’s +$4.75),
  • BioLife solutions (BLFS +$0.58),
  • Chinook therapeutics (KDNY +$0.57),

Hammered in today’s market (4 of 4):

  • Alnylam Pharmaceuticals (ALNY -$7.52 after Friday’s +$6.00),
  • Vericel (VCEL -$0.20),
  • Ionis Therapeutics (IONS -$0.17 after Friday’s +$1.86),
  • Bellicum Pharmaceuticals (BLCM -$0.10 after Friday’s -$0.04),

 

April, Q2/2022:

  • Monday closed positive with 31 incliners and 4 decliners
  • Friday closed positive with 27 incliners and 6 decliners and 2 flats

 

The BOTTOM LINE: On what (?) basis does this sector stay up as it can be a fickle place, as we’ve seen this year.

Is it just being ...Oversold or Overbought – they bunch and then alternate … as sessions evolve.

Are we entering a set-up for a selling opportunity?

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.